Myosana Therapeutics is at the forefront of developing a pioneering non-viral gene therapy platform aimed at treating neuromuscular and cardiac genetic diseases. This innovative platform addresses the limitations associated with traditional viral delivery methods, such as adeno-associated virus (AAV), which can only deliver smaller genes and often elicits immune responses that complicate repeated treatments. By utilizing a protein known as glucose transporter protein type-4 (GLUT4), Myosana's technology can transport larger genetic payloads directly into muscle cells, thereby expanding the range of treatable conditions. This approach not only enhances the safety profile of gene therapies but also allows for the possibility of redosing, which is crucial for the long-term management of genetic disorders.

The Myosana platform is particularly focused on conditions like Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy, both of which present significant challenges in current treatment paradigms. By enabling the delivery of full-length dystrophin genes rather than truncated versions, Myosana's technology holds the potential to significantly slow muscle degeneration and improve the quality of life for affected individuals. The company is committed to advancing this non-viral gene therapy approach, with plans to explore its applications across a broader spectrum of neuromuscular disorders and cardiomyopathies in the future.

United States

Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure.

Myosana Therapeutics

Company Details